PILA PHARMA AB

On July 10, 2025, PILA PHARMA AB concludes trading in unit rights related to its rights issue, resolved on June 19, 2025. The rights issue involves up to 9,994,019 units, with 19 unit rights allowing subscription for seven units, each priced at SEK 2.00. Each unit includes one new share and a warrant, enabling subscription for two new shares between February 5-15, 2026, at a price based on market averages, but not less than SEK 1.50 or more than SEK 3.00. The subscription period runs from July 1-15, 2025, with existing shareholders and management committing SEK 10.22 million, covering 51.12% of the issue, and additional guarantees of SEK 9.75 million, totaling 99.87% coverage. An over-allotment option of up to 4,963,773 units may be exercised if oversubscribed. PILA PHARMA, a Swedish biotech firm, focuses on developing TRPV1 antagonists for treating obesity and type 2 diabetes, with ongoing clinical trials and research collaborations. The company also explores applications for erythromelalgia and abdominal aorta aneurism. The press release includes disclaimers about distribution restrictions and forward-looking statements.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition to treat obesity and diabetes. The company participated in a podcast to discuss its proprietary TRPV1 inhibitor's potential in obesity studies and its ongoing rights issue, which is nearly fully covered by existing investors. The funds raised will support obesity studies aimed at creating a comprehensive data package for potential partnerships. PILA PHARMA focuses on developing drugs for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. The company has conducted successful phase 2a trials with its TRPV1 antagonist, XEN-D0501, showing good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. PILA PHARMA plans to progress into longer clinical trials and is preparing for a new trial to evaluate XEN-D0501's safety and efficacy in obesity and diabetes. The company also explores treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and plans for proof-of-concept studies.

PILA PHARMA AB, a Swedish biotech company, is developing new oral drugs targeting TRPV1 inhibition for obesity and diabetes treatment. The company is conducting a rights issue to fund a new venture focused on obesity studies, supported by existing investors and guarantor commitments. CEO Gustav H. Gram discusses the company's scientific approach and the rights issue in an interview with Finwire. PILA PHARMA aims to generate comprehensive data to facilitate partnerships. The company is also involved in projects related to type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. Their drug XEN-D0501 has shown promise in clinical trials for obesity and diabetes and has potential applications in other inflammatory and metabolic disorders. The company is preparing for further clinical trials to assess the safety and efficacy of XEN-D0501. Additionally, PILA PHARMA is exploring treatments for erythromelalgia and abdominal aorta aneurysm, with plans for clinical trials and potential out-licensing opportunities.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. The company is conducting a rights issue to fund a new venture focused on obesity studies, which is supported by existing investors and pre-commitments. CEO Gustav H. Gram discussed this initiative in an interview with Mathias Vahlne from Direkt Studios. PILA PHARMA aims to develop a comprehensive data package to facilitate partnerships. The company owns a TRPV1 asset, including the development candidate XEN-D0501, and holds patents for using TRPV1 antagonists in treating obesity and diabetes. XEN-D0501 has shown promising results in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The company is preparing for further clinical trials to evaluate the safety and efficacy of XEN-D0501. In addition to obesity and diabetes, PILA PHARMA is working on projects related to erythromelalgia and abdominal aorta aneurysm. The company collaborates with Uppsala University and has demonstrated preclinical proof-of-concept for using XEN-D0501 in reducing abdominal aorta aneurysm growth. PILA PHARMA's shares are traded on Nasdaq First North Growth Market in Sweden.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs using TRPV1 inhibition to treat obesity and diabetes. The company announced its participation in a new podcast episode with Joakim Båge from the 10X podcast, where CEO Gustav H. Gram discussed the company's plans to explore their TRPV1 inhibitor in obesity studies. They also talked about an ongoing rights issue, largely supported by existing investors, to fund these studies. PILA PHARMA aims to create a comprehensive data package to facilitate partnerships and continues to focus on developing drugs for obesity and diabetes. The company owns a TRPV1 asset, XEN-D0501, which has shown promise in clinical trials for treating obesity and diabetes. PILA PHARMA is also exploring treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research and development efforts in these areas.

PILA PHARMA AB has initiated a rights issue of units to raise approximately 20 million SEK, with the subscription period running from July 1 to July 15, 2025. Existing shareholders have preferential rights, and the issue includes a maximum of 9,994,019 units, each comprising one newly issued share and one warrant. The subscription price is SEK 2.00 per unit. The warrants allow holders to subscribe for additional shares between February 5 and February 15, 2026, at a price determined by the average market price, with certain limits. The company has secured commitments covering nearly the entire rights issue amount. An over-allotment issue may occur if the rights issue is oversubscribed. PILA PHARMA focuses on developing treatments for obesity, type 2 diabetes, and erythromelalgia using TRPV1 antagonists, specifically the compound XEN-D0501. The company is preparing for further clinical trials to assess safety and efficacy in treating these conditions. The press release includes legal disclaimers about distribution restrictions and forward-looking statements.

PILA PHARMA AB, a Swedish biotech company, announced a recent interview with Helge Larsen from ProInvestor, Denmark's largest online forum for investors in biotechnology and pharmaceuticals. During the interview, CEO Gustav H. Gram discussed the company's upcoming rights issue, which is nearly fully backed by investors and guarantors. The funds raised will support new obesity studies. PILA PHARMA focuses on developing TRPV1 antagonists, particularly XEN-D0501, for treating type 2 diabetes, obesity, erythromelalgia, and abdominal aorta aneurysm. XEN-D0501 has shown promise in clinical trials for diabetes and obesity, and research continues into its efficacy for other conditions. The company is preparing for further clinical trials and exploring potential treatments for obesity and related diseases.

PILA PHARMA AB announced that June 25, 2025, is the last day for trading shares that include rights to receive unit rights related to a rights issue resolved by the Board on June 19, 2025. Shareholders registered by June 27, 2025, will receive one unit right per share, with 19 unit rights allowing subscription for seven units. Each unit includes one new share and one warrant of series TO2, priced at SEK 2.00 per unit. The warrants, issued free of charge, allow holders to subscribe for two new shares between February 5-15, 2026, at a price determined by the average market price prior to February 5, 2026, but not less than SEK 1.50 or more than SEK 3.00 per share. The subscription period for the rights issue is from July 1-15, 2025, with existing shareholders and management committing approximately SEK 10.22 million, and additional guarantee commitments of SEK 9.75 million, covering nearly 99.87% of the issue. If oversubscribed, an over-allotment issue may be conducted. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for obesity and type 2 diabetes treatment, with its candidate XEN-D0501 showing promising results in clinical trials. The company is also exploring treatments for erythromelalgia and abdominal aorta aneurism. Legal and issuing advisors for the rights issue are MAQS Advokatbyrå and Nordic Issuing, respectively.

PILA PHARMA AB announced a rights issue of units, involving new shares and warrants, valued at approximately SEK 20 million. The Swedish Financial Supervisory Authority has approved the prospectus related to this issue. Shareholders as of June 27, 2025, will receive unit rights, allowing them to subscribe for new units at SEK 2.00 each. The subscription period is from July 1 to July 15, 2025. The company aims to use the proceeds primarily for preclinical trials of its drug candidate XEN-D0501 for obesity and for working capital. PILA PHARMA is a Swedish biotech firm focused on developing treatments for obesity and type 2 diabetes using TRPV1 antagonists. The company has completed phase 2a trials for XEN-D0501, showing positive results in enhancing insulin response and reducing heart failure biomarkers. The drug is also being explored for other conditions like erythromelalgia and abdominal aorta aneurism. The press release emphasizes that it is not an offer or solicitation for securities in jurisdictions where such actions would be unlawful.

PILA PHARMA AB's Board of Directors has announced a Rights Issue to raise approximately SEK 20 million by issuing new shares and warrants. The subscription price is set at SEK 2 per unit. Shareholders registered by June 27, 2025, will receive unit rights, allowing them to subscribe to new shares and warrants. The Rights Issue is supported by commitments from existing shareholders and management, covering about 99.87% of the total amount. If fully subscribed, the company will net approximately SEK 18 million after transaction costs. An Over-allotment Issue may be conducted if the Rights Issue is oversubscribed, potentially raising an additional SEK 9.9 million. The funds will primarily support the development of the company's drug candidate, XEN-D0501, targeting obesity and type 2 diabetes. The subscription period is from July 1 to July 15, 2025. The complete terms will be detailed in a prospectus expected to be published on June 25, 2025. PILA PHARMA is a Swedish biotech firm focused on developing treatments for obesity and diabetes, with interests in other diseases such as erythromelalgia and abdominal aortic aneurysm.